GlassScriptPhysician profile
Christopher D'Andrea
NPI 1053715979
$8,661.04
in general payments reported to CMS, 2019-2025
11 companies · $1,035 in 2025
The $1,035 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,585 · 2022: $773 · 2023: $4,314 · 2024: $954 · 2025: $1,035.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,100 · Food and Beverage: $2,573 · Travel and Lodging: $554 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,100.00 |
| Food and Beverage | $2,573.15 |
| Travel and Lodging | $554.19 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,680.42 | 2021-2025 | |
| Adaptive Biotechnologies Corporation | $800.00 | 2021 | |
| Incyte Corporation | $655.23 | 2022-2025 | Jakafi, Monjuvi, Jakafi |
| Genmab U.S., INC. | $415.64 | 2023-2025 | Epkinly |
| Astrazeneca Pharmaceuticals LP | $317.40 | 2021-2025 | Calquence |
| Epizyme, INC. | $185.82 | 2021-2022 | |
| Janssen Biotech, INC. | $151.72 | 2023-2024 | Rybrevant, Erleada, Akeega |
| Stemline Therapeutics INC. | $145.13 | 2024 | Orserdu |
| Beigene USA, INC. | $139.17 | 2024 | Brukinsa |
| E.R. Squibb & Sons, L.L.C. | $124.55 | 2025 | Breyanzi |
| Novo Nordisk INC | $45.96 | 2023-2024 | Ozempic, Rybelsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher D'Andrea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.